Anergis Overview
- Founded
- 2001
- Status
- Private
- Employees
- 11
- Latest Deal Type
- Series B
- Latest Deal Amount
- $30.7M
- Investors
- 12
Anergis General Information
Description
Developer of disease-modifying allergy immunotherapy intended to improve the medical treatment of patients suffering from allergies. The company's immunotherapy is based on a proprietary allergy vaccines targeting commercially attractive indications, enabling patients to get a long-term cure for allergies and reduce the treatment time.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- Biopôle Building SC-A
- Route de la Corniche 4
- 1066 Épalinges
- Switzerland
+41 021 000 00 00
Anergis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B) | 04-Apr-2016 | $30.7M | 000.00 | 000.00 | Completed | Generating Revenue |
| 3. Grant | 27-Sep-2013 | 000.00 | 000.00 | Completed | Generating Revenue | |
| 2. Later Stage VC (Series A) | 28-Mar-2011 | $19.6M | $22.8M | 000.00 | Completed | Generating Revenue |
| 1. Seed Round | $3.26M | $3.26M | Completed | Startup |
Anergis Executive Team (9)
Anergis Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Francois Spertini MD | Anergis | Founder, Chairman of Scientific Advisory Board & Vice Chairman of the Board of Directors | 000 0000 |
| Klaus Schollmeier Ph.D | Self | Chairman | 000 0000 |
| Markus Hosang Ph.D | BioMedPartners | Board Member | 000 0000 |
| Sten Verland Ph.D | Sunstone Life Science Ventures | Board Member | 000 0000 |
Anergis Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAnergis Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| BlueOcean Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Renaissance KMU Schweizerische Anlagestiftung | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| WJFS | Family Office | Minority | 000 0000 | 000000 0 | |
| BB Biotech Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Novartis Venture Fund | Corporate Venture Capital | 000 0000 | 000000 0 |